Clinical Trials Logo

Clinical Trial Summary

This is a first-in-human, Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of BJ-005 in patients with advanced solid tumor or lymphoma. BJ-005 is a recombinant bifunctional molecule, composed of a humanized anti-PD-L1 IgG1 monoclonal antibody (mAb) fused with a portion of the extracellular domain of human TGF-β receptor II (TGF-βRII).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05115292
Study type Interventional
Source BJ Bioscience, Inc.
Contact Joe Zhang, MD
Phone 203-437-6518
Email [email protected]
Status Recruiting
Phase Phase 1
Start date October 20, 2021
Completion date October 20, 2025